8-K: Valion Bio Completes $250K Stock and Warrant Sale

Valion Bio, Inc. announced the issuance of Series B Preferred Shares and warrants to 3i, LP for $250,000, as part of a larger potential financing.

Summary

• Valion Bio, Inc. (formerly Tivic Health Systems, Inc.) has completed a tranche of its financing agreement.
• On June 17, 2026, the company issued 250 shares of Series B Non-Voting Convertible Preferred Stock at $1,000 per share.
• Additionally, a warrant was issued to purchase 156,026 shares of common stock at an exercise price of $0.616280 per share.
• The aggregate purchase price for this tranche was $250,000.
• This transaction is part of a larger Securities Purchase Agreement originally entered into on April 29, 2025, with an investor, which was later assigned to 3i, LP.
• The total potential purchase price under the agreement is up to $8,400,000.
• The securities were issued under an exemption from registration pursuant to Section 4(a)(2) of the Securities Act of 1933 and/or Rule 506(b).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; while it brings in capital, it's a continuation of a financing round with potential dilution, and the total amount raised is still subject to future closings.

Positives

• Secured $250,000 in funding through the sale of preferred stock and warrants.
• Continued progress on a financing agreement that could total up to $8.4 million.
• The exercise price for the warrants is significantly below the current market price, suggesting potential future value for the company if the stock price increases.

Negatives

• The company is still reliant on raising capital through preferred stock and warrants, which can dilute existing shareholders.
• The total financing is being raised in tranches, indicating potential ongoing capital needs.

Risks

• The issuance of convertible preferred stock and warrants could lead to significant dilution for common stockholders upon conversion or exercise.
• The company's reliance on external financing suggests potential ongoing financial challenges.
• The terms of the original purchase agreement were amended, which could indicate evolving negotiations or challenges.

Future Outlook

The company has the potential to raise up to an additional $8,150,000 through subsequent tranches under the existing Securities Purchase Agreement, subject to the conditions outlined therein.

Industry Context

StockSavvy.ai notes that Valion Bio's reliance on preferred stock and warrant financing is common for early-stage or growth companies needing capital, but it highlights the ongoing need to demonstrate progress and de-risk the business to attract more traditional equity or debt financing.

Stakeholder Impact

• Common stockholders may experience dilution due to the issuance of preferred stock and warrants.
• 3i, LP becomes a significant investor in the company through this transaction.
• Employees and management will continue to work towards company objectives with the secured funding.

Next Steps

• Potential future closings under the Securities Purchase Agreement to raise additional capital up to $8,400,000.
• The company will continue to operate and potentially advance its business objectives with the secured funding.

Key Dates

Recommendation

The filing details a routine capital raise that is part of an ongoing financing. While it provides necessary funds, it doesn't offer new strategic information or significant positive catalysts to warrant a buy recommendation. The potential for dilution also tempers enthusiasm, making 'hold' appropriate until further operational or strategic developments are announced.

Keywords

Valion Bio, Tivic Health Systems, Form 8-K, Securities Purchase Agreement, Series B Preferred Stock, Warrants, Financing, 3i, LP